Cadonilimab: Clinical Trials

82 trials of Cadonilimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 recruiting, 24 unknown, 15 not yet recruiting, 9 active not recruiting. 66 Phase 2, 14 Phase 1, 5 Phase 3, 3 Not applicable, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 266Recruiting 23, Unknown 23, Not yet recruiting 11, Active not recruiting 8, Terminated 1
Phase 114Unknown 5, Active not recruiting 3, Recruiting 3, Not yet recruiting 2, Enrolling by invitation 1
Phase 35Recruiting 4, Active not recruiting 1
Not applicable3Recruiting 2, Enrolling by invitation 1
Early Phase 12Not yet recruiting 1, Recruiting 1

Follow Cadonilimab: new trials by email Literature Review of Cadonilimab trials Research Report on Cadonilimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
Larotrectinib, Cadonilimab, Plixorafenib - IDH Wildtype Glioblastoma, Glioblastoma (GBM)
Early Phase 1Not yet recruitingOlivia Newton-John Cancer Research Institute122027-03-012026-10-30
A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer
Cadonilimab, Megestrol Acetate (MA), Levonorgestrel-releasing intrauterine system - Endometrial Cancer
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University102026-10-012026-10-28
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Cadonilimab, CAPOX regimen, Nivolumab - Gastric / Gastroesophageal Junction Adenocarcinoma
Phase 3RecruitingAkeso9002026-09-242026-09-29
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
ateganosine, Cadonilimab - Resectable Hepatocellular Carcinoma
Early Phase 1RecruitingUniversity of Texas Southwestern Medical Center602026-09-012026-09-03
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Cadonilimab - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 2RecruitingMemorial Sloan Kettering Cancer Center372026-05-272026-09-23
Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT
Cadonilimab, RT - Locally Advanced Cervical Cancer
Phase 2Not yet recruitingRuijin Hospital452026-03-012026-03-05
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Cadonilimab, Capecitabine - Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms
Phase 2Not yet recruitingShanghai Zhongshan Hospital752025-11-282025-11-24
A Study of Ivonescimab in First-Line ES-SCLC
Ivonescimab, Cadonilimab, AK117 - Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Phase 2RecruitingAkeso1802025-10-292025-11-24
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Cadonilimab, SOX chemotherapy, Placebo - Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 3RecruitingAkeso7602025-08-142026-02-11
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
AK154, Cadonilimab, Ivonescimab (SMT112 or AK112) Injection - Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
Phase 1Not yet recruitingAkeso602025-07-222025-04-06
SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases
Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab - Advanced Gastric Cancer, Advanced Colorectal Cancer
Phase 1 / Phase 2Active not recruitingZhang Tao262025-03-202025-04-27
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Ligufalimab, Cadonilimab - Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma
Phase 2RecruitingUniversity of Texas Southwestern Medical Center642025-02-182026-02-27
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
IN10018, Nab-paclitaxel, Cadonilimab - Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology252025-02-172026-01-13
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Ivonescimab, Cadonilimab, Etoposide - Small Cell Lung Cancer
Phase 2RecruitingSichuan University802025-02-012025-01-10
Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Cadonilimab, radiotherapy, carboplatin, paclitaxel - Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages
Not applicableEnrolling by invitationFirst Affiliated Hospital of Ningbo University202024-12-012025-03-25
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
AK104, AK112, Chemotherapy - Recurrent Ovarian Cancer
Phase 2RecruitingAkeso1722024-11-122025-03-12
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
Cadonilimab, Adriamycin - Advanced Soft-tissue Sarcoma
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology532024-10-092025-07-18
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
AK112, Cadonilimab, AK127 - Hepatocellular Carcinoma
Phase 1 / Phase 2RecruitingAkeso2802024-09-242026-03-04
Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer
Cadonilimab - Cervical Cancer
RecruitingFujian Cancer Hospital2002024-09-072024-09-19
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
Cadonilimab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Neoadjuvant Chemoimmunotherapy
Phase 2RecruitingTongji Hospital502024-09-032024-09-19

Showing 20 of 82. Sign in to see all of them.

Conditions studied

Carcinoma, Hepatocellular (8)  ·  Uterine Cervical Neoplasms (8)  ·  Carcinoma, Non-Small-Cell Lung (6)  ·  Colorectal Neoplasms (5)  ·  Diabetes Mellitus, Insulin-Dependent, 12 (4)  ·  Endometrial Neoplasms (4)  ·  Nasopharyngeal Carcinoma (4)  ·  Stomach Neoplasms (4)  ·  Esophageal Squamous Cell Carcinoma (3)  ·  Small Cell Lung Carcinoma (3)  ·  Glioblastoma (2)  ·  Liver Neoplasms (2)  ·  Melanoma (2)  ·  Ovarian Neoplasms (2)  ·  Recurrence (2)

Sponsors

Akeso (9)  ·  Sun Yat-sen University (8)  ·  Fujian Cancer Hospital (4)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3)  ·  Guangzhou Institute of Respiratory Disease (2)  ·  Hunan Cancer Hospital (2)  ·  Peking University Cancer Hospital & Institute (2)  ·  Peking University Third Hospital (2)  ·  Sichuan University (2)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2)  ·  Tianjin Medical University Cancer Institute and Hospital (2)  ·  Tongji Hospital (2)  ·  University of Texas Southwestern Medical Center (2)  ·  Chinese Academy of Medical Sciences (1)

Countries

China (60)  ·  United States (5)  ·  Australia (1)  ·  Germany (1)  ·  Poland (1)

Top investigators

Lin Shen, MD (2)  ·  Amir Jazaeri (1)  ·  Anwen Liu, PhD (1)  ·  Baohui Han, M.D (1)  ·  Chong Zhao, MD, PhD (1)  ·  Chunxia Su, Phd (1)  ·  David Hsieh, MD (1)  ·  Ding Ma (1)  ·  Ge Lou, PHD (1)  ·  Guoxin Li, M.D., Ph.D (1)  ·  Han Dr. Gao (1)  ·  Hongqing Zhuang, M.D. (1)  ·  Hu Ma, Ph.D (1)  ·  Hui Gan, MBBS, FRACP (1)  ·  Hui Qiu, Ph.D. (1)

Results publications

PMID 28837405, PMID 29584545, PMID 31150573, PMID 35108470, PMID 35986837, PMID 36990609, PMID 37797632, PMID 37852261, PMID 38706247, PMID 40389320, PMID 40693391, PMID 40705040, PMID 40726978, PMID 41167638, PMID 41293180, PMID 41582028, PMID 42000370, PMID 42682622, PMID 42838953